Treatment Outcomes of Helical Intensity-Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background/Aims: This study reports treatment outcomes after helical intensity-modulated radiotherapy (IMRT) in unresectable hepatocellular carcinoma (HCC) patients for whom transarterial chemoembolization (TACE) was considered ineffective or unsuitable. Methods: From January 2008 to December 2011, 22 unresectable HCC patients received helical IMRT. A daily dose of 1.8 to 4 Gy was delivered at five fractions per week to deliver a total dose of 30 to 60 Gy. The most-prescribed dose fractionation was a total dose of 50 to 57.5 Gy, with a daily dose of 2.3 to 2.5 Gy. Results: In the entire group, the objective response rate of the primary tumor was 72.7%. In the eight patients with portal vein thrombosis (PVT), the objective response rate of PVT was 50.0%. Median disease progression-free survival was 11.8 months, and the 1-year disease progression-free survival rate was 40.2%. The median overall survival was 14.4 months, and the 1- and 2-year overall survival rates were 86.4% and 69.1%, respectively. PVT and Child-Pugh classifications were significant prognostic factors for overall survival in multivariate analyses. Conclusions: Helical IMRT in patients with unresectable HCC resulted in high treatment response and survival rates. This study suggests helical IMRT is a practical treatment option for HCC patients in whom TACE is unsuitable or ineffective.
Abstract
Background/Aims: This study reports treatment outcomes after helical intensity-modulated radiotherapy (IMRT) in unresectable hepatocellular carcinoma (HCC) patients for whom transarterial chemoembolization (TACE) was considered ineffective or unsuitable. Methods: From January 2008 to December 2011, 22 unresectable HCC patients received helical IMRT. A daily dose of 1.8 to 4 Gy was delivered at five fractions per week to deliver a total dose of 30 to 60 Gy. The most-prescribed dose fractionation was a total dose of 50 to 57.5 Gy, with a daily dose of 2.3 to 2.5 Gy. Results: In the entire group, the objective response rate of the primary tumor was 72.7%. In the eight patients with portal vein thrombosis (PVT), the objective response rate of PVT was 50.0%. Median disease progression-free survival was 11.8 months, and the 1-year disease progression-free survival rate was 40.2%. The median overall survival was 14.4 months, and the 1- and 2-year overall survival rates were 86.4% and 69.1%, respectively. PVT and Child-Pugh classifications were significant prognostic factors for overall survival in multivariate analyses. Conclusions: Helical IMRT in patients with unresectable HCC resulted in high treatment response and survival rates. This study suggests helical IMRT is a practical treatment option for HCC patients in whom TACE is unsuitable or ineffective.
참고문헌 (30)
- Poon RT, "Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective", Ann Surg, 235, pp.466~486 (2002)
- Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
- Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Krishnan S, "Radiotherapy for hepatocellular carcinoma: an overview", Ann Surg Oncol, 15, pp.1015~1024 (2008)
- Mackie TR, "Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy", Med Phys, 20, pp.1709~1719 (1993)
- Korean Liver Cancer Study Group and National Cancer Center, Korea, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Wang MH, "Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume", Int J Radiat Oncol Biol Phys, 76, pp.467~476 (2010)
- Wang W, "Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: definition of clinical target volume for radiotherapy", Radiat Oncol, 5, pp.73~ (2010)
- Fowler JF, "The linear-quadratic formula and progress in fractionated radiotherapy", Br J Radiol, 62, pp.679~694 (1989)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Lawrence TS, "The use of 3-D dose volume analysis to predict radiation hepatitis", Int J Radiat Oncol Biol Phys, 23, pp.781~788 (1992)
- Kim JH, "Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 69, pp.813~819 (2007)
- Cheng SH, "A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma", J Gastroenterol Hepatol, 14, pp.1025~1033 (1999)
- Seong J, "Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 43, pp.393~397 (1999)
- Guo WJ, "Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma", Br J Radiol, 73, pp.1091~1097 (2000)
- Liu MT, "Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization", Jpn J Clin Oncol, 34, pp.532~539 (2004)
- Kim TH, "Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable", Am J Clin Oncol, 29, pp.568~575 (2006)
- Mornex F, "Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies: mature results of the French Phase II RTF-1 trial", Int J Radiat Oncol Biol Phys, 66, pp.1152~1158 (2006)
- Kang MK, "High-dose radiotherapy with intensity-modulated radiation therapy for advanced hepatocellular carcinoma", Tumori, 97, pp.724~731 (2011)
- McIntosh A, "Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma", Cancer, 115, pp.5117~5125 (2009)
- Liang SX, "Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma", Cancer, 103, pp.2181~2188 (2005)
- Park HC, "Dose-response relationship in local radiotherapy for hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 54, pp.150~155 (2002)
- Park W, "Local radiotherapy for patients with unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 61, pp.1143~1150 (2005)
- Ben-Josef E, "Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies", J Clin Oncol, 23, pp.8739~8747 (2005)
- Zhou ZH, "Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma", Br J Radiol, 80, pp.194~201 (2007)
- 공문규, "Three Cases of Radiation-Induced Hepatitis B Virus Reactivation after Hepatic Tomotherapy: Case Report", Radiation oncology journal, 29(1), pp.53~62 (2011), 대한방사선종양학회
- Eccles CL, "Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies", Int J Radiat Oncol Biol Phys, 72, pp.582~588 (2008)
- Cheng JC, "Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease", Int J Radiat Oncol Biol Phys, 56, pp.229~234 (2003)